Working Towards a Cure:

CDI Continues Partnership with Rome Foundation


Commonwealth Diagnostics International, Inc (CDI) has renewed their commitment to the Rome Foundation, an independent 501(c)3 organization whose mission is to improve the lives of people with functional GI disorders. The foundation provides support for activities geared towards data and educational information, which assists in the diagnosis and treatment of Disorders of Gut Brain Interactions.

Millions of Americans suffer from the pain and discomfort of digestive diseases. According to the National Institute of Diabetes and Digestive and Kidney Diseases, 60 to 70 million people are affected by all digestive diseases. Through its ongoing support of the Rome Foundation, CDI will continue to collaborate on the development of educational industry resources and clinical guidelines.

“This long-standing partnership is critical to ongoing research efforts necessary to identify modern solutions and approaches to diagnosing, treating, and caring for patients with digestive diseases,” said Craig Strasnick, CEO of CDI, the leader in Hydrogen and Methane Breath Testing whose mission is to aid in the diagnosis of functional gastrointestinal disorders. “We look forward to our continued support and sponsorship of the Rome Foundation’s advocacy efforts and serving as part of the foundation’s advisory council.”

The Rome Criteria, developed through the Rome Foundation, is used by medical providers to diagnose Irritable Bowel Syndrome (IBS) and other GI disorders that can impact the quality of life for millions of people. In 2018, CDI re-launched IBSchek®, a proprietary blood test based on the scientific findings of a 2,500+ patient clinical trial that showed anti-vinculin and anti-CdtB are effective biomarkers for the diagnosis of IBS-D and IBS-M. These key biomarkers have been included in the Rome Foundation’s official Rome IV Clinical Decision Toolkit, an online resource to assist practitioners in achieving optimal clinical outcomes.

To achieve the best treatment for digestive disease patients, CDI will continue to support The Rome Foundation’s research initiatives and development of education tools for providers.

Continued Strasnick, “Having worked together since 2016, we are excited about the future of this partnership as we work towards advancing the diagnosis and treatment of gastrointestinal disorders in the US and globally.”